ArticleBlood advances2019
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- [A rare case of Rosai-Dorfman disease involving the pituitary stalk and presenting initially with diabetes insipidus].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Clinicopathological insights into ophthalmic Rosai-Dorfman disease: A 15-year retrospective analysis.Indian journal of ophthalmology · 2026Article
- Mixed histiocytosis of Langerhans cell with Rosai-Dorfman disease.JAAD case reports · 2025Article
- Insights into etiology and management of a case of Langerhans cell histiocytosis manifesting as perianal lesions: a case report.Journal of medical case reports · 2025Article
- Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.Molecular biotechnology · 2025Review
- Updates on Langerhans cell histiocytosis and other histiocytosis in children: invited review-challenges and novelties in paediatric tumours.Virchows Archiv : an international journal of pathology · 2025Review
- Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients.Frontiers in oncology · 2025Article
- Extranodal Rosai-Dorfman disease masquerading as intrathoracic invasive malignancy with ankylosing spondylitis: a case report.Journal of cardiothoracic surgery · 2024Article
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Cranial Rosai-Dorfman disease: a case report and literature review.Frontiers in oncology · 2024Article
- Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.Paediatric drugs · 2023Review
- Primary diffuse Rosai-Dorfman disease in central airway: a case report and literature review.BMC pulmonary medicine · 2023Review
- Review
- Case report:Frontiers in medicine · 2022Article
- Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.Journal of inflammation research · 2022Article
- Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.Blood advances · 2020Article
- BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.Acta neuropathologica communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.